Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 137 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)				Phase IV				G-PCNSL-SG1 NCT00153530
	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors				Phase III, Phase II				RPCI-I-72806 I 72806, NCT00536601
	Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP				Phase III				DSHNHL 2006-1B / ACT-2 BMBF GFVT 01014715, NCT00725231
	Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma				Phase II, Phase I				RTOG-0227 NCT00068250
	Rituximab, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma				Phase II, Phase I				OHSU-1012 OHSU-SOL-05025-L, NCT00293475
	Allogeneic Cytokine-Induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies				Phase II, Phase I				CIK#2/2007 NMRC/1097/2006, NCT00460694
	A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With T-Cell Diseases				Phase II, Phase I				FDA IND 100712 96-MH-01, NCT00611208
	A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies				Phase II, Phase I				CLBH589B2102 NCT00621244
	Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation				Phase II, Phase I				25223 PSU25223, NCT00626626
	Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies				Phase II, Phase I				8717 NCT00673114


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute